Mutual of America Capital Management LLC Has $20.75 Million Stock Position in Danaher Co. (NYSE:DHR)

Mutual of America Capital Management LLC reduced its stake in shares of Danaher Co. (NYSE:DHR) by 3.6% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 83,035 shares of the conglomerate’s stock after selling 3,096 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Danaher were worth $20,746,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in DHR. Oak Thistle LLC acquired a new stake in Danaher in the second quarter valued at approximately $363,000. Caden Capital Partners LP increased its position in Danaher by 12.4% during the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after acquiring an additional 15,313 shares during the period. JARISLOWSKY FRASER Ltd increased its position in Danaher by 10.8% during the fourth quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock worth $132,524,000 after acquiring an additional 55,908 shares during the period. HighPoint Advisor Group LLC acquired a new stake in Danaher during the fourth quarter worth $2,614,000. Finally, Norden Group LLC acquired a new stake in Danaher during the first quarter worth $4,151,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of NYSE:DHR opened at $272.48 on Wednesday. The company has a market capitalization of $201.82 billion, a price-to-earnings ratio of 46.18, a P/E/G ratio of 4.48 and a beta of 0.83. The firm’s 50 day simple moving average is $265.91 and its 200 day simple moving average is $256.78. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period last year, the company posted $2.05 EPS. As a group, sell-side analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 in the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Evercore ISI decreased their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. The Goldman Sachs Group lifted their price target on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Bank of America boosted their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.